HighTower Advisors LLC Trims Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

HighTower Advisors LLC lessened its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 4.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 756,823 shares of the biopharmaceutical company’s stock after selling 36,255 shares during the period. HighTower Advisors LLC’s holdings in Sangamo Therapeutics were worth $772,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. E Fund Management Co. Ltd. purchased a new position in shares of Sangamo Therapeutics during the fourth quarter worth about $25,000. PNC Financial Services Group Inc. lifted its position in Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in Sangamo Therapeutics during the fourth quarter valued at approximately $28,000. Shelton Wealth Management LLC purchased a new position in Sangamo Therapeutics in the 4th quarter worth approximately $29,000. Finally, Sageworth Trust Co bought a new position in shares of Sangamo Therapeutics in the 4th quarter worth $61,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SGMO shares. Truist Financial reduced their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Wells Fargo & Company cut their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.82 on Friday. The company has a market capitalization of $184.26 million, a P/E ratio of -1.09 and a beta of 1.49. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The stock has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. As a group, equities analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.